Update on Biomarkers of Hepatocellular Carcinoma

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 2, 2015, Pages 237-245

  Chaiteerakij, Roongruedee ^a,b   Addissie, Benyam D ^a   Roberts, Lewis R ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

^b KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

Early detection; Liver cancer; Prognosis; Prognostic factor; Tumor; Fetoprotein

Indexed keywords

BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; EPITHELIAL CELL ADHESION MOLECULE; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; GLYPICAN 3; MICRORNA; OSTEOPONTIN; SCATTER FACTOR RECEPTOR;

ALLELE; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CLINICAL PRACTICE; GENETIC ASSOCIATION; GENOMICS; HUMAN; INDIVIDUALIZATION; LABORATORY TEST; LIVER CELL CARCINOMA; METABOLOMICS; PROTEOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL (TOPIC); EARLY DIAGNOSIS; LIVER NEOPLASMS; PROCEDURES;

BIOMARKERS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; EARLY DETECTION OF CANCER; HUMANS; LIVER NEOPLASMS;

EID: 84927695900     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.10.038     Document Type: Review

References (53)

1. Tian Q., Price N.D., Hood L. Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. JIntern Med 2012, 271:111-121.
2. Kipp B.R., Stadheim L.M., Halling S.A., et al. Acomparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004, 99:1675-1681.
3. Pepe M.S., Etzioni R., Feng Z., et al. Phases of biomarker development for early detection of cancer. JNatl Cancer Inst 2001, 93:1054-1061.
4. Lee E., Edward S., Singal A.G., et al. Improving screening for hepatocellular carcinoma by incorporating data on levels of alpha-fetoprotein, over time. Clin Gastroenterol Hepatol 2013, 11:437-440.
5. Wright K, Harrod E, Webb G, et al. Alpha-fetoprotein measurement in the diagnosis of hepatocellular carcinoma in real-life practice: A multi-centre, retrospective analysis. Gut 2013, 62(Suppl1):A177-A178.
6. Shang S., Plymoth A., Ge S., et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012, 55:483-490.
7. Gavilan J.C., Ojeda G., Arnedo R., et al. Predictive factors of risk of hepatocellular carcinoma in chronic hepatitis C. Eur J Intern Med 2013, 24:846-851.
8. Lee M.H., Yang H.I., Liu J., et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology 2013, 58:546-554.
9. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. JCancer Res Clin Oncol 2004, 130:417-422.
10. McMahon B.J., Bulkow L., Harpster A., et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000, 32:842-846.
11. Singal A.G., Conjeevaram H.S., Volk M.L., et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012, 21:793-799.
12. Zhang B., Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. JMed Screen 1999, 6:108-110.
13. Marrero J.A., Feng Z., Wang Y., et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009, 137:110-118.
14. Marrero J.A., Su G.L., Wei W., et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003, 37:1114-1121.
15. Nakamura S., Nouso K., Sakaguchi K., et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006, 101:2038-2043.
16. Baek Y.H., Lee J.H., Jang J.S., et al. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepato-gastroenterology 2009, 56:763-767.
17. Xu C., Yan Z., Zhou L., et al. Acomparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis. JCancer Res Clin Oncol 2013, 139:1417-1424.
18. Chong C.C., Lee K.F., Ip P.C., et al. Pre-operative predictors of post-hepatectomy recurrence of hepatocellular carcinoma: can we predict earlier?. Surgeon 2012, 10:260-266.
19. Giannini E.G., Marenco S., Borgonovo G., et al. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology 2012, 56:1371-1379.
20. Berry K., Ioannou G.N. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl 2013, 19:634-645.
21. Memon K., Kulik L., Lewandowski R.J., et al. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. JHepatol 2012, 56:1112-1120.
22. Chan S.L., Mo F.K., Johnson P.J., et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. JClin Oncol 2009, 27:446-452.
23. Yang J.D., Kim W.R., Park K.W., et al. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. Hepatology 2012, 56:614-621.
24. Llovet J.M., Pena C.E., Lathia C.D., et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012, 18:2290-2300.
25. Nakazawa T., Hidaka H., Takada J., et al. Early increase in alpha-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2013, 25:683-689.
26. Tanaka T., Taniguchi T., Sannomiya K., et al. Anovel des-gamma-carboxy prothrombin in serum for the diagnosis of hepatocellular carcinoma. JGastroenterol Hepatol 2013, 28:1348-1355.
27. Chen M., Li G., Yan J., et al. Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clin Chim Acta 2013, 423C:105-111.
28. el-Houseini M.E., Mohammed M.S., Elshemey W.M., et al. Enhanced detection of hepatocellular carcinoma. Cancer Control 2005, 12:248-253.
29. Clifford R.J., Zhang J., Meerzaman D.M., et al. Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology 2010, 52:2034-2043.
30. Zhang H., Zhai Y., Hu Z., et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010, 42:755-758.
31. Li S., Qian J., Yang Y., et al. GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet 2012, 8:e1002791.
32. Jiang D.K., Sun J., Cao G., et al. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet 2013, 45:72-75.
33. Kumar V., Kato N., Urabe Y., et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 2011, 43:455-458.
34. Miki D., Ochi H., Hayes C.N., et al. Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet 2011, 43:797-800.
35. Guyot E., Sutton A., Rufat P., et al. PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis. JHepatol 2013, 58:312-318.
36. Marrero J.A., Romano P.R., Nikolaeva O., et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. JHepatol 2005, 43:1007-1012.
37. Wang M., Long R.E., Comunale M.A., et al. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2009, 18:1914-1921.
38. Tian L., Wang Y., Xu D., et al. Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases. Int J Cancer 2011, 129. 1923-1231.
39. Qi J., Wang J., Katayama H., et al. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma 2013, 60:135-142.
40. Tomimaru Y., Eguchi H., Nagano H., et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. JHepatol 2012, 56:167-175.
41. Wang B., Chen D., Chen Y., et al. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. JProteome Res 2012, 11:1217-1227.
42. Zhang A., Sun H., Yan G., et al. Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry. Clin Chim Acta 2013, 418:86-90.
43. Nault J.C., De Reynies A., Villanueva A., et al. Ahepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 2013, 145:176-187.
44. Boyault S., Rickman D.S., de Reynies A., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45:42-52.
45. Lee J.S., Chu I.S., Heo J., et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40:667-676.
46. Arao T., Ueshima K., Matsumoto K., et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 2013, 57:1407-1415.
47. Kondo S., Ojima H., Tsuda H., et al. Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma. Int J Clin Oncol 2013, 18:207-213.
48. Santoro A., Rimassa L., Borbath I., et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncology 2013, 14:55-63.
49. Jiang J., Gusev Y., Aderca I., et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008, 14:419-427.
50. Budhu A., Jia H.L., Forgues M., et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008, 47:897-907.
51. Sato F., Hatano E., Kitamura K., et al. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One 2011, 6:e16435.
52. Schulze K., Gasch C., Staufer K., et al. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 2013, 133:2165-2171.
53. Sun Y.F., Xu Y., Yang X.R., et al. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 2013, 57:1458-1468.